Project Grant R21AR083597
Award Date 9/20/23
Completion Date 9/19/25
Dollars Obligated $378K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
William Penn Annex West, PA 19107, USA
Similar Awards
- This federal Project Grant award of $777,869 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) supports a randomized, double-blind, controlled, multi-center clinical trial to investigate the use of colchicine in treating Calcium Pyrophosphate Deposition Disease (CPPD), a prevalent but underserved form of inflammatory arthritis. The goal is to better understand colchicine's impact on the NLRP3 inflammasome and downstream pathways, which play a key role in CPPD...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $761,042 to the University of Pittsburgh to conduct research on the mechanisms driving medial arterial calcification (MAC) in peripheral artery disease (PAD). The key objectives are to: 1) define how the DNA damage response promotes vascular calcification, and 2) determine how reduced adenosine production alters arginine methylation to upregulate osteogenic gene...
- This Project Grant award of $429,000.00 from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), supports research on the biogenesis and function of cyclic phosphate-containing small non-coding RNAs (CP-RNAs). The award, effective February 8, 2025 through December 31, 2029, will enable a genome-wide expression analysis of short CP-RNAs across various cells and tissues. Key objectives include: 1) determining that...
- This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), is funding a $239,488 research project to characterize the inflammatory pathologies underlying axial psoriatic arthritis (AxPsA) using total-body positron emission tomography/computed tomography (TB-PET/CT) imaging. The primary objectives are to: 1) derive consolidated, whole-spine...
- This $379,003 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) aims to leverage the awardee's experience in uncovering regulatory factors of heparan sulfate (HS) biosynthesis to identify genes that control the expression of EXT1 and EXT2 genes, which are key contributors to the development of Multiple Hereditary Exostoses (MHE). The goal is to discover...
- This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846), will provide $175,948 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to investigate the molecular mechanisms underlying the synergistic effects of mechanical loading and hormonal signaling in bone cells. The research aims to identify how focal...
- This $300,000 Project Grant award was provided by the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) to the University of Rochester. The project aims to "Decipher the Endotypes and Signature of Non-Response in a Humanized Murine Model of PSA" for psoriatic arthritis, a chronic inflammatory disease. The research will (1) identify cellular and molecular signatures across psoriatic arthritis tissue domains, (2) define CD8+ T cell...
- The University of Rochester was awarded a $464,315 Project Grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846). The purpose of this 5-year project, beginning on July 1, 2025, is to investigate the role of the L-type Ca2+ channel Cav1.2 in the development of Achilles tendinopathy. The research aims to identify early mediators in tendons in response to...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $331,051 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to Tufts Medical Center Parent, Inc. The award will fund a 3-year study examining the use of Veverimer, a non-absorbable polymer, to decrease net acid excretion and bone resorption in adults with osteopenia. The study aims to evaluate Veverimer as a novel treatment to reverse the adverse effects of...
- This federal Project Grant award, valued at $164,830.00 and provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports research led by Dr. Alexis Ogdie at the University of Pennsylvania. The primary objectives are to: 1) quantify the impact and interrelationships of potentially modifiable risk factors, including obesity, depression, and anxiety, on treatment response...